{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:46:16Z","timestamp":1767707176004},"reference-count":102,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Int. J. Endo. Oncol."],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.2217\/ije-2015-0004","type":"journal-article","created":{"date-parts":[[2016,4,8]],"date-time":"2016-04-08T22:07:51Z","timestamp":1460153271000},"page":"175-189","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Update on Management of Midgut Neuroendocrine Tumors"],"prefix":"10.1080","volume":"3","author":[{"given":"Amir","family":"Mehrvarz Sarshekeh","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M","family":"Halperin","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,4,8]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(63)90951-6"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.4502"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.10.1502"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01185.x"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000335629"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb2a5"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90422-0"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377"},{"issue":"2","key":"e_1_3_2_11_1","first-page":"133","article-title":"Carcinoid syndrome: a statistical evaluation of 748 reported cases","volume":"18","author":"Soga J","year":"1999","unstructured":"Soga J , YakuwaY, OsakaM. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J. Exp. Clin. Cancer Res.18(2), 133\u2013141 (1999).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"e_1_3_2_12_1","volume-title":"American Society of Clinical Oncology (ASCO) Annual Meeting 2012","author":"Choti MA","year":"2012","unstructured":"Choti MA , BobiakS, StrosbergJR, AlE. Prevalence of functional tumors in neuroendocrine carcinoma: an analysis from the NCCN NET database (abstract). Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2012. Chicago, IL, USA, 20 May 2012."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-007-0452-1"},{"key":"e_1_3_2_14_1","unstructured":"AJCC Cancer Staging Manual (7th edition) . Springer Chicago IL USA (2010)."},{"key":"e_1_3_2_15_1","volume-title":"WHO Classification of Tumours of the Digestive System (4th Ed)","author":"Rindi G","year":"2010","unstructured":"Rindi G , ArnoldR, BosmanFT, AlE. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System (4th Ed). BosmanTF, CarneiroF, HrubanRH, TheiseND (Eds). International Agency for Research on Cancer (IARC), Lyon, France (2010)."},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0011"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0042"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-002-6630-z"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000197899"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1072-7515(03)00230-8"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.9262"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.179.4068.77"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-2736(03)00235-9"},{"issue":"3","key":"e_1_3_2_25_1","first-page":"320","article-title":"Secretion of somatostatin and its physiologic function","volume":"109","author":"Reichlin S","year":"1987","unstructured":"Reichlin S . Secretion of somatostatin and its physiologic function. J. Lab Clin. Med.109(3), 320\u2013326 (1987).","journal-title":"J. Lab Clin. Med."},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601253340408"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100451"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1385\/MO:20:1:59"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04174.x"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl105"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/10.suppl_2.S17"},{"issue":"24","key":"e_1_3_2_32_1","first-page":"6977","article-title":"Oncological applications of somatostatin analogues","volume":"48","author":"Schally AV","year":"1988","unstructured":"Schally AV . Oncological applications of somatostatin analogues. Cancer Res.48(24 Pt 1), 6977\u20136985 (1988).","journal-title":"Cancer Res."},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-92-1-68"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2008.02.002"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198609113151102"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198511073131916"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.600"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"e_1_3_2_39_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.4030","article-title":"Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results on long-term survival","volume":"31","author":"Arnold R","year":"2013","unstructured":"Arnold R , WittenbergM, RinkeAet al. Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results on long-term survival. J. Clin. Oncol.31(Suppl.), Abstract 4030 (2013).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28653"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31821f66b4"},{"issue":"10","key":"e_1_3_2_42_1","first-page":"4127","article-title":"High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors","volume":"29","author":"Chadha MK","year":"2009","unstructured":"Chadha MK , LombardoJ, MashtareTet al. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res.29(10), 4127\u20134130 (2009).","journal-title":"Anticancer Res."},{"issue":"3","key":"e_1_3_2_43_1","first-page":"326","article-title":"Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses","volume":"35","author":"Ferolla P","year":"2012","unstructured":"Ferolla P , FaggianoA, GrimaldiFet al. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J. Endocrinol. Invest.35(3), 326\u2013331 (2012).","journal-title":"J. Endocrinol. Invest."},{"issue":"3","key":"e_1_3_2_44_1","first-page":"81","article-title":"Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors","volume":"6","author":"Strosberg J","year":"2013","unstructured":"Strosberg J , WeberJ, FeldmanM, GoldmanJ, AlmhannaK, KvolsL. Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors. Gastrointest. Cancer Res.6(3), 81\u201385 (2013).","journal-title":"Gastrointest. Cancer Res."},{"key":"e_1_3_2_45_1","volume-title":"European Society of Medical Oncology (ESMO) Annual Meeting","author":"Markovich A","year":"2012","unstructured":"Markovich A , EmelianovaG, GorbounovaV, BruzginV, OrelN. Long acting octreotide in pts with disseminated neuroendocrine tumors. Presented at: European Society of Medical Oncology (ESMO) Annual Meeting. Vienna, Austria, 28 September\u20132 October 2012."},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S84177"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i6.1945"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.2.279"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1159\/000082875"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.142"},{"key":"e_1_3_2_52_1","volume-title":"American Society of Clinical Oncology (ASCO) Annual Meeting","author":"Caplin ME","year":"2014","unstructured":"Caplin ME , RuszniewskiPB, PavelMEet al. Progression-free survival (PFS) with lanreotide autogel\/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, USA, 30 May\u20133 June 2014."},{"key":"e_1_3_2_53_1","volume-title":"American Society of Clinical Oncology (ASCO) Annual Meeting 2015","author":"Dasari A","year":"2015","unstructured":"Dasari A , PhanAT, CaplinMEet al. Lanreotide depot\/autogel (LAN) in midgut neuroendocrine tumors (NETs): a subgroup analysis from the CLARINET study. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2015. Chicago, IL, USA, 29 May\u20132 June 2015."},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1460707"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2007.09.006"},{"issue":"11","key":"e_1_3_2_56_1","first-page":"36","article-title":"Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects","volume":"28","author":"Hofland LJ","year":"2005","unstructured":"Hofland LJ , Van Der HoekJ, FeeldersR, Van Der LelyAJ, De HerderW, LambertsSW. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J. Endocrinol. Invest.28(11 Suppl. International), 36\u201342 (2005).","journal-title":"J. Endocrinol. Invest."},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0367"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0360"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2000-0001"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0120"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0012"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh216"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2012.12.002"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23323"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.7.865"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1997.tb00965.x"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70143-0"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198307213090301"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.4149"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860310010547"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.1998.00321.x"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22554"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.3147"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1478-7"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.6374"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.001"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.4004"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9020"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70136-1"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv252"},{"issue":"18","key":"e_1_3_2_81_1","article-title":"MC044h, a Phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study","volume":"25","author":"Hobday TJ","year":"2007","unstructured":"Hobday TJ , RubinJ, HolenKet al. MC044h, a Phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J. Clin. Oncol. Part I25(18S), Abstract 4504 (2007).","journal-title":"J. Clin. Oncol. Part I"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1476"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.616"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.11.1255"},{"issue":"4","key":"e_1_3_2_85_1","first-page":"327","article-title":"Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"2","author":"Moertel CG","year":"1979","unstructured":"Moertel CG , HanleyJA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin. Trials2(4), 327\u2013334 (1979).","journal-title":"Cancer Clin. Trials"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0173"},{"key":"e_1_3_2_87_1","unstructured":"Lexicon Pharmaceuticals\n. Telotristat Etiprate (LX1032). www.lexgen.com\/pipeline\/telotristat-etiprate.html."},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2330-6"},{"issue":"5","key":"e_1_3_2_89_1","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC","volume":"43","author":"Waldherr C","year":"2002","unstructured":"Waldherr C , PlessM, MaeckeHRet al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J. Nucl. Med.43(5), 610\u2013616 (2002).","journal-title":"J. Nucl. Med."},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011160913619"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/bip.10349"},{"issue":"10","key":"e_1_3_2_92_1","first-page":"1556","article-title":"Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors","volume":"44","author":"Bushnell D","year":"2003","unstructured":"Bushnell D , O\u2019dorisioT, MendaYet al. Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. J. Nucl. Med.44(10), 1556\u20131560 (2003).","journal-title":"J. Nucl. Med."},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-1023-y"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2006.01.001"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8585"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2553"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1159\/000225951"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000113"},{"key":"e_1_3_2_99_1","unstructured":"Advanced Accelerator Applications\n. AAA Announces Positive Results From Phase 3 Study NETTER-1 Evaluating Lutathera in Patients with Advanced Midgut Neuroendocrine Tumors. www.adacap.com\/flash-news\/2015\/09\/aaa-announces-positive-results-from-Phase-3-study-netter-1-evaluating-lutathera-in-patients-with-advanced-midgut-neuroendocrine-tumors-3\/."},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603419"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-10-0126"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-07-0202"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61742-X"},{"key":"e_1_3_2_104_1","unstructured":"Novartis Global\n. Novartis drug Afinitor \u00ae significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET. www.novartis.com\/news\/media-releases\/novartis-drug-afinitor%C2%AE-significantly-improves-progression-free-survival."}],"container-title":["International Journal of Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/ije-2015-0004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:16:02Z","timestamp":1715958962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/ije-2015-0004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,8]]},"references-count":102,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.2217\/ije-2015-0004"],"URL":"https:\/\/doi.org\/10.2217\/ije-2015-0004","relation":{},"ISSN":["2045-0869","2045-0877"],"issn-type":[{"value":"2045-0869","type":"print"},{"value":"2045-0877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iije20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iije20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}